JP2022042891A - Composition for antimicrobial water - Google Patents
Composition for antimicrobial water Download PDFInfo
- Publication number
- JP2022042891A JP2022042891A JP2020148557A JP2020148557A JP2022042891A JP 2022042891 A JP2022042891 A JP 2022042891A JP 2020148557 A JP2020148557 A JP 2020148557A JP 2020148557 A JP2020148557 A JP 2020148557A JP 2022042891 A JP2022042891 A JP 2022042891A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- water
- mass
- antibacterial
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000000845 anti-microbial effect Effects 0.000 title abstract 8
- 229940024606 amino acid Drugs 0.000 claims abstract description 16
- 235000001014 amino acid Nutrition 0.000 claims abstract description 16
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229930064664 L-arginine Natural products 0.000 claims abstract description 6
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 6
- 229960002885 histidine Drugs 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims abstract description 5
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 63
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 239000003899 bactericide agent Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 8
- 241000714201 Feline calicivirus Species 0.000 description 7
- 230000002421 anti-septic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 238000002156 mixing Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- -1 Fatty acid ester Chemical class 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本発明は、抗菌水用組成物に関し、特に、安全性を有する抗菌水用組成物に関する。 The present invention relates to an antibacterial water composition, and more particularly to a safe antibacterial water composition.
抗菌水には一般的に、中身や容器が微生物により腐敗などの変性を起こさないように、微生物の繁殖や成育を抑制する防腐・殺菌成分が配合されている。多くの防腐・殺菌成分は、配合可能成分リスト（ポジティブリスト）に記載されているので、配合規制がある。 Antibacterial water generally contains antiseptic and bactericidal components that suppress the growth and growth of microorganisms so that the contents and containers do not undergo denaturation such as putrefaction by microorganisms. Since many antiseptic and bactericidal ingredients are listed in the compoundable ingredient list (positive list), there are compounding restrictions.
例えば、殺菌剤を含む拭き取り用の抗菌水であって、敏感肌用、ニキビ予防用、及びニキビ改善用からなる群より選ばれた用途に用いられ、下記成分（Ａ）、下記成分（Ｂ）、下記成分（Ｃ）、下記成分（Ｄ）、及び下記成分（Ｅ）を含むことを特徴とする抗菌水が知られている（特許文献１）。
成分（Ａ）：抗炎症剤
成分（Ｂ）：殺菌剤
成分（Ｃ）：脂肪酸エステル非イオン性界面活性剤
成分（Ｄ）：保湿剤
成分（Ｅ）：水
For example, antibacterial water for wiping containing a bactericidal agent, which is used for applications selected from the group consisting of for sensitive skin, for acne prevention, and for acne improvement, and has the following components (A) and the following components (B). , The following component (C), the following component (D), and the following component (E) are known as antibacterial water (Patent Document 1).
Ingredient (A): Anti-inflammatory agent Ingredient (B): Bactericide Ingredient (C): Fatty acid ester Nonionic surfactant Ingredient (D): Moisturizer Ingredient (E): Water
このように、上述の特許文献１を含め従来技術においては、中身や容器が微生物により腐敗などの変性を起こさないように、殺菌剤を含むものが多いのが現状である。一方で、未だにこれらの抗菌成分等は有害であるという認識を持つ消費者が多いことから、防腐・殺菌剤を配合しないことが望まれる。したがって、使用する前に、内容物や容器が微生物により腐敗などの変性を起こさないように、防腐・殺菌成分以外の手段によって、微生物の繁殖や成育を抑制することができれば望ましい。 As described above, in the prior art including the above-mentioned Patent Document 1, many of them contain a bactericidal agent so that the contents and the container are not denatured by microorganisms such as putrefaction. On the other hand, since many consumers still recognize that these antibacterial components and the like are harmful, it is desirable not to add preservatives and bactericidal agents. Therefore, it is desirable that the growth and growth of microorganisms can be suppressed by means other than antiseptic and bactericidal components so that the contents and containers are not denatured by microorganisms such as putrefaction before use.
そこで、本発明は、抗菌力を有し、安全性を有する抗菌水組成物を提供することにある。 Therefore, the present invention is to provide an antibacterial water composition having antibacterial activity and safety.
上記目的を達成するために、本発明者らは、防腐、殺菌成分を配合することなく、抗菌性を有する組成物について鋭意検討した結果、本発明を見出すに至った。 In order to achieve the above object, the present inventors have found the present invention as a result of diligent studies on a composition having antibacterial properties without blending antiseptic and bactericidal components.
すなわち、本発明の抗菌水用組成物は、Ｌ－システイン、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン、又はこれらの塩類の少なくとも1種のアミノ酸を含有する抗菌水用組成物であって、前記抗菌水用組成物のｐHは１０．９以上であることを特徴とする。 That is, the antibacterial water composition of the present invention is an antibacterial water composition containing at least one amino acid of L-cysteine, L-arginine, L-lysine, L-histidine, or salts thereof. The antibacterial water composition is characterized by having a pH of 10.9 or more.
また、本発明の抗菌水用組成物の好ましい実施態様において、さらに、還元性イオン水を含有することを特徴とする。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, it is further characterized by containing reducing ionized water.
また、本発明の抗菌水用組成物の好ましい実施態様において、抗菌水用組成物の全量に対して、前記アミノ酸の含有量は、１．０質量％～０．００００１質量％の範囲であることを特徴とする。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, the content of the amino acid is in the range of 1.0% by mass to 0.00001% by mass with respect to the total amount of the antibacterial water composition. It is characterized by.
また、本発明の抗菌水用組成物の好ましい実施態様において、抗菌水用組成物の全量に対して、前記還元性イオン水の含有量は、１０質量％～９０質量％の範囲であることを特徴とする。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, the content of the reducing ionized water is in the range of 10% by mass to 90% by mass with respect to the total amount of the antibacterial water composition. It is a feature.
また、本発明の抗菌水用組成物の好ましい実施態様において、ｐH調整剤を含有しないことを特徴とする。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, it is characterized by not containing a pH adjuster.
本発明の抗菌水用組成物によれば、いわゆる防腐剤や殺菌剤を配合せず、抗菌性を有する抗菌水用組成物の提供が可能であるという有利な効果を奏する。 According to the antibacterial water composition of the present invention, it is possible to provide an antibacterial water composition having antibacterial properties without adding a so-called preservative or bactericidal agent, which is an advantageous effect.
本発明の抗菌水用組成物は、Ｌ－システイン、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン、又はこれらの塩類の少なくとも1種のアミノ酸を含有する抗菌水用組成物であって、前記抗菌水用組成物のｐHは１０．９以上、より好ましくは、１１．５以上であることを特徴とする。これは、抗菌成分等の添加を望まない消費者に対して、いわゆる防腐・殺菌剤を配合せずに、抗菌作用を有する組成物を提供しようとするものである。なお、Ｌ－システイン及びその塩類は毛髪の保湿および柔軟性を保たせることが可能であり、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン等は毛髪の損傷により毛髪から流出するため、添加することにより、アミノ酸成分を補充することも可能となる。 The antibacterial water composition of the present invention is an antibacterial water composition containing at least one amino acid of L-cysteine, L-arginine, L-lysine, L-histidine, or salts thereof. The pH of the water composition is 10.9 or more, more preferably 11.5 or more. This is an attempt to provide a composition having an antibacterial action to a consumer who does not want to add an antibacterial component or the like without adding a so-called antiseptic / bactericidal agent. In addition, L-cysteine and its salts can keep the hair moisturized and soft, and L-arginine, L-lysine, L-histidine and the like flow out from the hair due to damage to the hair, so they should be added. Therefore, it is possible to supplement the amino acid component.
このように、本発明においては、アルカリ度が極めて低いため塗布されたときに肌の中和能で瞬時に弱酸性になり、肌に刺激のない抗菌水とすることができる。したがって、肌に塗布される前は、ｐＨ１０．９以上～ｐＨ１１．５付近なので防腐剤を配合しなくても抗菌性のある抗菌水であり、肌に塗布されると瞬時に弱酸性（肌表面でｐＨ６．０付近）になることを特徴の一つとすることができる。 As described above, in the present invention, since the alkalinity is extremely low, the water becomes weakly acidic instantly due to the neutralizing ability of the skin when applied, and the antibacterial water that does not irritate the skin can be obtained. Therefore, before it is applied to the skin, it is an antibacterial water that has antibacterial properties even if it does not contain preservatives because it has a pH of 10.9 or higher and is around pH 11.5. It can be one of the features that the pH is around 6.0).
また、本発明の抗菌水用組成物の好ましい実施態様において、前記アミノ酸の含有量は、抗菌水用組成物の全量に対して、１．０質量％～０．００００１質量％の範囲、より好ましくは、０．０１質量％～０．０００１質量％の範囲であることを特徴とする。かかる範囲としたのは、この程度の量であれば、抗菌性を有する組成物として効果を発揮し得るからである。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, the content of the amino acid is more preferably in the range of 1.0% by mass to 0.00001% by mass with respect to the total amount of the antibacterial water composition. Is in the range of 0.01% by mass to 0.0001% by mass. The reason for setting this range is that an amount of this degree can be effective as a composition having antibacterial properties.
本発明において、ｐH値の調整は、配合するアミノ酸の種類、配合量等により適宜調整可能である。一般に、炭酸ナトリウムの他、炭酸ソーダ、炭酸水素ナトリウム等を含めｐH調整剤を用いて調整することができるが、このようなｐH調整剤の使用は、組成物のアルカリ度が高くなりｐＨを維持する力は強くなり、肌に塗布した場合は瞬時に弱酸性には戻りづらくなる傾向がある。 In the present invention, the pH value can be appropriately adjusted depending on the type of amino acid to be blended, the blending amount, and the like. Generally, it can be adjusted by using a pH adjuster including sodium carbonate, sodium carbonate, sodium hydrogen carbonate, etc. in addition to sodium carbonate, but the use of such a pH adjuster increases the alkalinity of the composition and maintains the pH. When applied to the skin, it tends to be difficult to instantly return to weak acidity.
したがって、かかる観点から、本発明の好ましい実施態様において、ｐH調整剤を含有しないことを特徴とする。 Therefore, from this point of view, in a preferred embodiment of the present invention, the pH adjuster is not contained.
また、本発明において、前記抗菌水用組成物のｐHは１０．９以上であるとしたのは、このようなｐH値であれば、いわゆる防腐・殺菌成分を添加しなくても、多くの好アルカリ性微生物を排除することが可能だからである。 Further, in the present invention, the pH of the antibacterial water composition is set to 10.9 or more because such a pH value is preferable even if a so-called antiseptic / bactericidal component is not added. This is because it is possible to eliminate alkaline microorganisms.
また、本発明の抗菌水用組成物の好ましい実施態様において、さらに、還元性イオン水を含有することを特徴とする。上述のように、ｐH値の調整は、配合するアミノ酸の種類、配合量等により適宜調整可能であるが、配合するアミノ酸や配合量によっては、所望のpH値を達成できない虞もある。この場合には、還元性イオン水を使用することができる。還元イオン水は、電気分解され、アルカリ性を示す水とすることができる。例えば、還元イオン水としては、株式会社エー・アイ・システムプロダクトが製造販売するＳ－１００等を挙げることができ、Ｓ-１００は、、電気分解された高機能還元性イオン水で、化粧品表示名称は「水」、ｐＨ１２±０．５のアルカリ性水である。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, it is further characterized by containing reducing ionized water. As described above, the pH value can be appropriately adjusted depending on the type and amount of the amino acid to be blended, but the desired pH value may not be achieved depending on the amino acid to be blended and the blending amount. In this case, reducing ionized water can be used. The reduced ionized water can be electrolyzed into water showing alkalinity. For example, examples of the reduced ionized water include S-100 manufactured and sold by AI System Products Co., Ltd. The S-100 is electrolyzed highly functional reducing ionized water and is labeled as cosmetics. The name is "water", which is alkaline water with a pH of 12 ± 0.5.
また、本発明の抗菌水用組成物の好ましい実施態様において、抗菌水用組成物の全量に対して、前記還元性イオン水の含有量は、１０質量％～９０質量％の範囲、より好ましくは、１０質量％～２０質量％の範囲であることを特徴とする。 Further, in a preferred embodiment of the antibacterial water composition of the present invention, the content of the reducing ionized water is in the range of 10% by mass to 90% by mass, more preferably to the total amount of the antibacterial water composition. It is characterized in that it is in the range of 10% by mass to 20% by mass.
以下では本発明の抗菌水用組成物の一例について実施例を用いて説明するが、本発明は、下記の実施例に限定して解釈されるものではない。 Hereinafter, an example of the antibacterial water composition of the present invention will be described with reference to Examples, but the present invention is not construed as being limited to the following Examples.
実施例１
まず、アルカリ性を呈し、防腐・殺菌成分を配合しない頭髪・肌の抗菌水用組成物の一例を試みた。アミノ酸の一例として、アルギニンを用いた。具体的に、精製水99.0質量％にＬ(+)―アルギニン（和光純薬工業（株）製）１．０％質量を配合して、アルカリ性水溶液を作成しｐＨを測定した。また、参照のため、精製水８０．０質量％に電解還元性イオン水Ｓ－１００（（株）エー・アイ・システムプロダクト製）を２０質量％配合し、アルカリ性水溶液を作成しｐＨを測定した。
Example 1
First, we tried an example of an antibacterial water composition for hair and skin that is alkaline and does not contain antiseptic and bactericidal components. Arginine was used as an example of the amino acid. Specifically, 1.0% by mass of L (+)-arginine (manufactured by Wako Pure Chemical Industries, Ltd.) was mixed with 99.0% by mass of purified water to prepare an alkaline aqueous solution, and the pH was measured. For reference, 20% by mass of electrolytically reducing ionized water S-100 (manufactured by AI System Product Co., Ltd.) was added to 80.0% by mass of purified water to prepare an alkaline aqueous solution and measure the pH. ..
なお、ｐＨ測定には以下の機種及び電極を用いた。
ｐＨメーターの機種：pH METER F-71（（株）堀場製作所）
ｐＨメーターの電極：＃9615-10D（（株）堀場製作所）
The following models and electrodes were used for pH measurement.
Model of pH meter: pH METER F-71 (HORIBA, Ltd.)
pH meter electrode: # 9615-10D (HORIBA, Ltd.)
実施例２
次に、精製水７９．０質量％にＳ－１００を２０．０質量％、Ｌ－アルギニン１．０質量％を配合して、アルカリ性水溶液を作成し、実施例１と同様にｐＨを測定した。
Example 2
Next, 20.0% by mass of S-100 and 1.0% by mass of L-arginine were mixed with 79.0% by mass of purified water to prepare an alkaline aqueous solution, and the pH was measured in the same manner as in Example 1. ..
表１に、実施例１～２、参照例のｐＨ測定値を示す。 Table 1 shows the pH measured values of Examples 1 and 2 and Reference Examples.
表１の結果から参照例のｐＨ測定値が一番高いことが判明した。 From the results in Table 1, it was found that the pH measurement value of the reference example was the highest.
実施例３～６
表１の結果をもとに、実施例１と同様の手順に従って、種々の調整例を作成した。表２は、本発明の一実施態様における抗菌水用組成物の成分例及び調整例を示す。
Examples 3 to 6
Based on the results in Table 1, various adjustment examples were created according to the same procedure as in Example 1. Table 2 shows component examples and preparation examples of the antibacterial water composition according to one embodiment of the present invention.
実施例７
次に、アミノ酸として、L-ヒスチジンを用いて、かつ、種々の量の還元イオン水を用いて、上述の実施例の手順に従って、本発明の抗菌水用組成物を作成した。その結果を、表４に示す。
Example 7
Next, using L-histidine as an amino acid and using various amounts of reduced ionized water, the composition for antibacterial water of the present invention was prepared according to the procedure of the above-mentioned Examples. The results are shown in Table 4.
これらの結果、ｐＨ１０．９以上の組成物を作成することができ、いわゆる防腐剤、殺菌剤を含むことなく、抗菌性を有する組成物を作成するできることが判明した。また、仮に、３種類の塩基性アミノ酸を同量配合する場合には、０．００１％以下が好ましいことが判明した。 As a result, it was found that a composition having a pH of 10.9 or higher can be prepared, and a composition having antibacterial properties can be prepared without containing so-called preservatives and bactericides. Further, it was found that 0.001% or less is preferable when the same amount of three kinds of basic amino acids is blended.
また、本発明においては、炭酸ナトリウムの他、炭酸ソーダ、炭酸水素ナトリウム等のｐH調整剤を使用していないので、アルカリ度が極めて低い組成物を提供することができるので肌に塗布されたときに肌の中和能で瞬時に弱酸性になり肌を刺激しないという有利な効果を奏する。さらに、本発明の組成物を頭髪に塗布した場合にはアルカリ性の時に毛髪への浸透性を高め、塩基性アミノ酸を補うことが可能であることが判明した。 Further, in the present invention, since a pH adjuster such as sodium carbonate or sodium hydrogen carbonate is not used in addition to sodium carbonate, a composition having extremely low alkalinity can be provided, so that when applied to the skin, it can be provided. In addition, it has the advantageous effect of instantly becoming weakly acidic due to the neutralizing ability of the skin and not irritating the skin. Furthermore, it has been found that when the composition of the present invention is applied to hair, it is possible to enhance the permeability to hair when it is alkaline and to supplement basic amino acids.
実施例８
次に、実際に、本発明の抗菌水用組成物について、各種ウイルスを用いて、当該ウイルスの不活性化効果を調べた。具体的に、本発明の抗菌水用組成物と、インフルエンザウイルス、ネコカリシウイルス、PEDウイルスとを反応させた時のウイルス不活化効果を確認した。対照資材として滅菌リン酸緩衝液を使用した。ウイルス不活化試験に使用した本発明の抗菌水用組成物の成分を、表５に示す。
Example 8
Next, the antibacterial water composition of the present invention was actually investigated using various viruses for the inactivating effect of the virus. Specifically, the virus inactivating effect when the composition for antibacterial water of the present invention was reacted with influenza virus, feline calicivirus, and PED virus was confirmed. Sterile phosphate buffer was used as a control material. The components of the antibacterial water composition of the present invention used in the virus inactivation test are shown in Table 5.
供試微生物については、以下の通りである。
・インフルエンザウイルス：swine influenza virus H1N1 IOWA株、培養細胞： MDCK細胞 （イヌ腎臓由来株化細胞）
・ネコカリシウイルス：feline calicivirus F9 株、培養細胞： CRFK細胞 （ネコ腎臓由来株化細胞）※ノロウイルス代替
・PEDウイルス： Porcine epidemic diarrhea virus P-5V 株、培養細胞： vero細胞（アフリカミドリザルの腎臓上皮由来株化細胞）※豚感染性のコロナウイルス（新型コロナウイルス代替として）
The test microorganisms are as follows.
・ Influenza virus: swine influenza virus H1N1 IOWA strain, cultured cells: MDCK cells (strain derived from canine kidney)
・ Feline calicivirus F9 strain, cultured cells: CRFK cells (feline kidney-derived strained cells) * Norovirus substitute
・ PED virus: Porcine epidemic diarrhea virus P-5V strain, cultured cells: vero cells (cells derived from kidney epithelium of African green monkey) * Pig infectious coronavirus (as an alternative to the new coronavirus)
試験区等の設定については、試験区においては、以下の通りである。
処置：試験資材（本発明の抗菌水用組成物）1mLにウイルス液0.1mL添加
感作時間：試験開始後30分
The setting of the test plots, etc. is as follows in the test plots.
Treatment: Add 0.1 mL of virus solution to 1 mL of test material (composition for antibacterial water of the present invention) Sensitization time: 30 minutes after the start of the test
対照区においては、以下の通りである。
処置：リン酸緩衝液1mLにウイルス液0.1mL添加
感作時間：試験開始後 0分、 30 分
In the control area, it is as follows.
Treatment: Add 0.1 mL of virus solution to 1 mL of phosphate buffer Sensitization time: 0 minutes, 30 minutes after the start of the test
試験方法については、「ウイルス実験学 総論 改訂二版 丸善株式会社 ウイルス中和試験法」を参考として実施した 。 The test method was carried out with reference to "Virus Experiments General Remarks Revised 2nd Edition Maruzen Co., Ltd. Virus Neutralization Test Method".
＜試験 手順＞
１）予備試験：
試験に先立って、試験資材が培養細胞に与える影響（細胞毒性）を調査した。試験資材をリン酸緩衝液で10倍段階希釈した後、培養細胞に接種し、培養後の細胞の正常な状態を示す最高濃度を確認し、試験に使用するウイルス濃度を決定した。その結果、細胞毒性について、MDCK細胞、CRFK細胞、vero細胞のいずれにおいても確認されなかった。この為、各ウイルス添加濃度は105 TCID50 /mL以上、検出限界は<101.5TCID50/mLとした。
<Test procedure>
1) Preliminary test:
Prior to the test, the effect of the test material on cultured cells (cytotoxicity) was investigated. After diluting the test material 10-fold with phosphate buffer, the cultured cells were inoculated, the maximum concentration indicating the normal state of the cultured cells was confirmed, and the virus concentration used for the test was determined. As a result, cytotoxicity was not confirmed in any of MDCK cells, CRFK cells, and vero cells. Therefore, the concentration of each virus added was 10 5 TCID 50 / mL or more, and the detection limit was <10 1.5 TCID 50 / mL.
２）本試験・試験液混合：
試験区分に従い、試験資材及びリン酸緩衝液の各1mLをそれぞ分取し、予備試験で決定した濃度にウイルス液を添加した。ウイルス液添加後、混合液として室温（25℃）にて所定の時間静置した。
2) Main test / test solution mixing:
According to the test classification, 1 mL each of the test material and the phosphate buffer was separated, and the virus solution was added to the concentration determined in the preliminary test. After adding the virus solution, the mixture was allowed to stand at room temperature (25 ° C.) for a predetermined time.
３）本試験・細胞接種及び菌数測定：
試験区分ごとに感作が終了した混合液をそれぞれ10倍段階希釈し、96wellプレートに培養した細胞に100μLずつ接種した。判定は、37℃、炭酸ガス培養（5％）で5日間培養した後、インフルエンザウイルスの場合は、各ウェル内の培養上清を回収し、赤血球凝集反応によりウイルスの増殖の有無を確認し、その濃度を算出した。また、ネコカリシウイルス及び PEDウイルスの場合は、培養細胞を顕微鏡観察し、培養細胞に現れるCPE（細胞変性）をもってウイルス増殖の有無を確認し、その濃度を算出した。
3) This test ・ Cell inoculation and bacterial count measurement:
The sensitized mixture was diluted 10-fold in each test category, and 100 μL of the cells cultured on 96-well plates was inoculated. Judgment is made by culturing in carbon dioxide gas culture (5%) at 37 ° C for 5 days, and in the case of influenza virus, collect the culture supernatant in each well and confirm the presence or absence of virus growth by hemagglutination reaction. The concentration was calculated. In the case of feline calicivirus and PED virus, the presence or absence of virus growth was confirmed by CPE (cytopathic effect) appearing in the cultured cells by observing the cultured cells under a microscope, and the concentration was calculated.
＜結果＞
１）インフルエンザウイルス
インフルエンザウイルスに対する試験結果を図1にした。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった（108.1TCID50/mL（130000000））。試験区では開始後30分で103.9TCID50/mL（8000）（99.99％減少）となった。
<Result>
1) Influenza virus Figure 1 shows the test results for influenza virus. No change in viral load was observed in the control group from the start of the test to 30 minutes (10 8.1 TCID 50 / mL (130000000)). In the test plot, it was 10 3.9 TCID 50 / mL (8000) (99.99% decrease) 30 minutes after the start.
２）PEDウイルス
PEDウイルスに対する試験結果を図2に示した。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった （108.1TCID50/mL（130000000））。試験区では開始後30分で103.9TCID50/mL（8000）（99.99％減少）となった。
2) PED virus
Figure 2 shows the test results for the PED virus. No change in viral load was observed in the control group from the start of the test to 30 minutes (10 8.1 TCID 50 / mL (130000000)). In the test plot, it was 10 3.9 TCID 50 / mL (8000) (99.99% decrease) 30 minutes after the start.
３）ネコカリシウイルス
ネコカリシウイルスに対する試験結果を図3に示した。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった（106.7TCID50/mL（5000000））。試験区では開始後30分で101.9TCID50/mL（99.99％減少）となった。
3) Feline calicivirus The test results for feline calicivirus are shown in Fig. 3. No change in viral load was observed in the control group from the start of the test to 30 minutes (10 6.7 TCID 50 / mL (5000000)). In the test plot, it was 10 1.9 TCID 50 / mL (99.99% decrease) 30 minutes after the start.
今回、試験資材のインフルエンザウイルス、ネコカリシウイルス及びPEDウイルスに対する不活化効果試験を実施した。その結果、試験資材（本発明の抗菌水用組成物）はインフルエンザウイルス、ネコカリシウイルス、及びPEDウイルスに対して30分以上の反応で99.99％以上のウイルス不活化効果があることが判明した。 This time, we conducted an inactivation effect test of the test materials against influenza virus, feline calicivirus and PED virus. As a result, it was found that the test material (the antibacterial water composition of the present invention) has a virus inactivating effect of 99.99% or more in a reaction of influenza virus, feline calicivirus, and PED virus for 30 minutes or more.
本発明によると、防腐剤、殺菌剤を配合することなく、抗菌性を有することから、広い分野において産業上利用価値が高い。 According to the present invention, since it has antibacterial properties without blending preservatives and bactericides, it has high industrial utility value in a wide range of fields.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020148557A JP2022042891A (en) | 2020-09-03 | 2020-09-03 | Composition for antimicrobial water |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020148557A JP2022042891A (en) | 2020-09-03 | 2020-09-03 | Composition for antimicrobial water |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2022042891A true JP2022042891A (en) | 2022-03-15 |
Family
ID=80641560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020148557A Pending JP2022042891A (en) | 2020-09-03 | 2020-09-03 | Composition for antimicrobial water |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2022042891A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023171556A1 (en) * | 2022-03-10 | 2023-09-14 | 積水化学工業株式会社 | Viral infection inhibitor, viral infection inhibiting product, viral infection inhibiting paint, and resin composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007050400A (en) * | 2005-07-20 | 2007-03-01 | Ai System Product:Kk | Method for producing minus ion water, and minus ion water |
| WO2017094905A1 (en) * | 2015-12-02 | 2017-06-08 | 金印株式会社 | Hair restoration/growth stimulating agent |
| JP2019019097A (en) * | 2017-07-19 | 2019-02-07 | 株式会社サニープレイス | Hair cosmetic composition |
-
2020
- 2020-09-03 JP JP2020148557A patent/JP2022042891A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007050400A (en) * | 2005-07-20 | 2007-03-01 | Ai System Product:Kk | Method for producing minus ion water, and minus ion water |
| WO2017094905A1 (en) * | 2015-12-02 | 2017-06-08 | 金印株式会社 | Hair restoration/growth stimulating agent |
| JP2019019097A (en) * | 2017-07-19 | 2019-02-07 | 株式会社サニープレイス | Hair cosmetic composition |
Non-Patent Citations (2)
| Title |
|---|
| "S-100および弊社原料によるウイルス不活化と殺菌効力試験のご報告", 株式会社エー・アイ・システムプロダクト, vol. [令和4年7月27日検索], JPN6022031832, 6 August 2020 (2020-08-06), pages インターネット, ISSN: 0005020262 * |
| 新 化粧品ハンドブック, JPN6022031834, 2006, pages 392 - 411, ISSN: 0005020261 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023171556A1 (en) * | 2022-03-10 | 2023-09-14 | 積水化学工業株式会社 | Viral infection inhibitor, viral infection inhibiting product, viral infection inhibiting paint, and resin composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5554926B2 (en) | Antiviral method | |
| US7510721B2 (en) | Multi-purpose acid compositions | |
| AU2013359955B2 (en) | Synergistic disinfection enhancement | |
| ES2547310T3 (en) | Method for reducing and / or maintaining the total viable bacterial count in mineral preparations comprising aqueous ground natural calcium carbonate and / or precipitated calcium carbonate and / or dolomite and / or calcium carbonate that has been reacted on the surface | |
| CN108605933B (en) | Fatty acid compound | |
| JP2022042891A (en) | Composition for antimicrobial water | |
| CN110917196A (en) | Chloroquine antibacterial disinfectant and application thereof | |
| CN110292045A (en) | A kind of antimicrobial compositions preparation method and application containing epsilon-polylysine | |
| EP0375149B1 (en) | Virucidal low toxicity compositions | |
| JP6165953B1 (en) | Virus inactivating agent and sanitary material for vesivirus and / or norovirus | |
| JP2016113373A (en) | Water-soluble composition having antibacterial and antiviral properties | |
| JP2017105723A (en) | Composition having calicivirus inactivation effect | |
| JP2015205234A (en) | Vomit treatment agent | |
| JP6531234B1 (en) | Virus inactivating agent, norovirus inactivating agent and hygiene material | |
| JP2021175709A (en) | Lotion composition | |
| CN112120042A (en) | Hypochlorous acid disinfectant with efficient sterilization function and preparation method thereof | |
| JP2008533086A (en) | An isothiazolone-containing preservative with improved efficacy. | |
| JP6234627B1 (en) | Norovirus inactivator and sanitary material | |
| CN113475530B (en) | Stable disinfectant and preparation method thereof | |
| CN114946890A (en) | Biological environment-friendly disinfectant product for efficiently killing new coronavirus and preparation method thereof | |
| WO2011072728A1 (en) | Composition in form of a gel for the virucidal disinfection of mammalian skin | |
| CN111742925B (en) | Environment-friendly long-acting washing-free sterilizing disinfectant and preparation and use methods thereof | |
| JP2023075484A (en) | antibacterial method | |
| CN111328811B (en) | Low-concentration alcohol sterilization disinfectant and application thereof | |
| JP7080461B2 (en) | Virus inactivating agents, norovirus inactivating agents and sanitary materials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220916 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230201 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230201 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230209 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230302 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230331 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230421 |